JP2004516013A5 - - Google Patents

Download PDF

Info

Publication number
JP2004516013A5
JP2004516013A5 JP2002514188A JP2002514188A JP2004516013A5 JP 2004516013 A5 JP2004516013 A5 JP 2004516013A5 JP 2002514188 A JP2002514188 A JP 2002514188A JP 2002514188 A JP2002514188 A JP 2002514188A JP 2004516013 A5 JP2004516013 A5 JP 2004516013A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
nucleic acid
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002514188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516013A (ja
Filing date
Publication date
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/en
Priority claimed from US09/643,657 external-priority patent/US6642024B1/en
Priority claimed from PCT/US2000/023522 external-priority patent/WO2001016319A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/en
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Priority claimed from US09/747,259 external-priority patent/US6569645B2/en
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/en
Priority claimed from US09/767,609 external-priority patent/US20020042367A1/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/en
Priority claimed from PCT/US2001/006666 external-priority patent/WO2001066740A2/en
Priority claimed from US09/816,744 external-priority patent/US6579520B2/en
Priority claimed from US09/828,366 external-priority patent/US20020010137A1/en
Priority claimed from US09/854,280 external-priority patent/US7115398B2/en
Priority claimed from US09/866,034 external-priority patent/US20030170864A1/en
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/en
Priority claimed from US09/866,028 external-priority patent/US6642360B2/en
Priority claimed from US09/870,574 external-priority patent/US6551799B2/en
Priority claimed from PCT/US2001/017443 external-priority patent/WO2002016611A2/en
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/en
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/en
Application filed filed Critical
Priority claimed from PCT/US2001/021735 external-priority patent/WO2002008284A2/en
Publication of JP2004516013A publication Critical patent/JP2004516013A/ja
Publication of JP2004516013A5 publication Critical patent/JP2004516013A5/ja
Withdrawn legal-status Critical Current

Links

JP2002514188A 2000-07-20 2001-07-09 血管形成に関連する障害を診断及び治療するための組成物と方法 Withdrawn JP2004516013A (ja)

Applications Claiming Priority (36)

Application Number Priority Date Filing Date Title
US21955600P 2000-07-20 2000-07-20
US22062400P 2000-07-25 2000-07-25
US22066400P 2000-07-25 2000-07-25
PCT/US2000/020710 WO2001009327A2 (en) 1999-07-28 2000-07-28 Method of preventing the injury or death of retinal cells and treating ocular diseases
US22269500P 2000-08-02 2000-08-02
US09/643,657 US6642024B1 (en) 1998-01-29 2000-08-17 Guanylate-binding protein
PCT/US2000/023522 WO2001016319A2 (en) 1999-08-31 2000-08-23 Compositions and methods for the treatment of immune related diseases
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US23097800P 2000-09-07 2000-09-07
US66535000A 2000-09-18 2000-09-18
US66461000A 2000-09-18 2000-09-18
US24292200P 2000-10-24 2000-10-24
US70923800A 2000-11-08 2000-11-08
PCT/US2000/030952 WO2001049715A2 (en) 2000-01-06 2000-11-08 Methods and compositions for inhibiting neoplastic cell growth
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/034956 WO2001046420A2 (en) 1999-12-23 2000-12-20 Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
US09/747,259 US6569645B2 (en) 1999-05-14 2000-12-20 IL-17 homologous polypeptides and therapeutic uses thereof
US09/767,609 US20020042367A1 (en) 1997-11-25 2001-01-22 Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US79649801A 2001-02-28 2001-02-28
PCT/US2001/006520 WO2001068848A2 (en) 2000-03-01 2001-02-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/006666 WO2001066740A2 (en) 2000-03-03 2001-03-01 Compositions and methods for the treatment of immune related diseases
US80270601A 2001-03-09 2001-03-09
US80868901A 2001-03-14 2001-03-14
US09/816,744 US6579520B2 (en) 1998-05-15 2001-03-22 IL-17 related mammalian cytokine polypeptides (IL-17E)
US09/828,366 US20020010137A1 (en) 1997-09-18 2001-04-05 Methods and compositions for inhibiting neoplastic cell growth
US09/854,280 US7115398B2 (en) 1998-05-15 2001-05-10 IL-17 homologous polypeptides and therapeutic uses thereof
US09/854,208 US7217412B2 (en) 1998-05-15 2001-05-10 IL-17C related mammalian cytokine polypeptides
US09/866,034 US20030170864A1 (en) 2000-05-30 2001-05-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/017092 WO2001092331A2 (en) 2000-05-30 2001-05-25 Compositions and methods for the treatment of immune related diseases
US09/866,028 US6642360B2 (en) 1997-12-03 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
US09/870,574 US6551799B2 (en) 1999-12-07 2001-05-30 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
PCT/US2001/017443 WO2002016611A2 (en) 2000-08-24 2001-05-30 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
PCT/US2001/017800 WO2001093983A1 (en) 2000-06-02 2001-06-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/019692 WO2002000690A2 (en) 2000-06-23 2001-06-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PCT/US2001/021735 WO2002008284A2 (en) 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Related Child Applications (4)

Application Number Title Priority Date Filing Date
JP2008194678A Division JP2009039117A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194721A Division JP2009039118A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194764A Division JP2009039119A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2011173336A Division JP6033531B2 (ja) 2000-07-20 2011-08-08 血管形成に関連する障害を診断及び治療するための組成物と方法

Publications (2)

Publication Number Publication Date
JP2004516013A JP2004516013A (ja) 2004-06-03
JP2004516013A5 true JP2004516013A5 (enExample) 2010-07-15

Family

ID=99797957

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2002514188A Withdrawn JP2004516013A (ja) 2000-07-20 2001-07-09 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194764A Withdrawn JP2009039119A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194678A Withdrawn JP2009039117A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194721A Withdrawn JP2009039118A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2011173336A Expired - Fee Related JP6033531B2 (ja) 2000-07-20 2011-08-08 血管形成に関連する障害を診断及び治療するための組成物と方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2008194764A Withdrawn JP2009039119A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194678A Withdrawn JP2009039117A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194721A Withdrawn JP2009039118A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2011173336A Expired - Fee Related JP6033531B2 (ja) 2000-07-20 2011-08-08 血管形成に関連する障害を診断及び治療するための組成物と方法

Country Status (5)

Country Link
EP (1) EP1309685A2 (enExample)
JP (5) JP2004516013A (enExample)
AU (1) AU2001271973A1 (enExample)
CA (1) CA2416538A1 (enExample)
WO (1) WO2002008284A2 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012179A2 (en) 1997-09-12 2000-06-28 Apotech R&D S.A. Cysteine rich receptors: trail
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030119113A1 (en) 1999-07-20 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1200590B1 (en) 1999-08-12 2009-01-07 Agensys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
EP1621620A3 (en) * 1999-09-01 2006-05-10 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2349679T3 (es) 1999-10-28 2011-01-10 Agensys, Inc. Antígeno tumoral secretado.
DK1897944T3 (da) * 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
WO2001081401A1 (en) 2000-04-21 2001-11-01 Fuso Pharmaceutical Industries, Ltd. Novel collectins
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2792747A1 (en) * 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2075253A1 (en) * 2000-06-23 2009-07-01 Genentech, Inc. Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
US7164009B2 (en) 2000-09-15 2007-01-16 Genentech, Inc. Pro9821 polypeptides
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
WO2002036625A2 (en) 2000-11-03 2002-05-10 The Regents Of The University Of California Prokineticin polypeptides, related compositions and methods
EP1334179A2 (en) 2000-11-14 2003-08-13 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells lsi-01
US20030125521A1 (en) 2001-06-20 2003-07-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20030228319A1 (en) * 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1530590A2 (en) * 2002-03-22 2005-05-18 Bioxell S.p.a. Triggering receptors expressed on myeloid cells (trem)-4 and -5 and uses thereof
CA2480419A1 (en) * 2002-03-28 2003-10-09 Yamanouchi Pharmaceutical Co., Ltd. Antiopoietin-related growth factor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AU2003261911A1 (en) * 2002-09-04 2004-03-29 Takeda Pharmaceutical Company Limited Use of disease-associated gene
WO2004024076A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2004028479A2 (en) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
DK1641822T3 (da) 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
CN102895663A (zh) 2004-04-14 2013-01-30 健泰科生物技术公司 含有用于调节血管发育的egfl7拮抗剂的组合物及方法
PL1781682T3 (pl) 2004-06-24 2013-08-30 Mayo Found Medical Education & Res Polipeptyd kostymulujący B7-H5
RU2007104022A (ru) 2004-07-02 2008-08-10 Дженентек, Инк. (Us) Композиции для лечения неходжкинской лимфомы и способы их применения
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
HRP20161580T1 (hr) 2008-05-06 2016-12-30 Genentech, Inc. CRIg-VARIJANTE S RAZVIJENIM AFINITETOM
MX2011008430A (es) 2009-02-20 2011-09-29 Ganymed Pharmaceuticals Ag Metodos y composiciones para diagnostico y tratamiento del cancer.
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
RU2011149798A (ru) 2009-05-08 2013-06-20 Дженентек, Инк. Гуманизированные анти-egfl7-антитела и способы их применения
AT508569A1 (de) 2009-07-23 2011-02-15 Affiris Ag Pharmaceutical compound
EP3689911B1 (en) 2009-11-11 2024-08-21 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3026064B1 (en) 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
PT2945642T (pt) * 2013-01-17 2024-05-27 Medizinische Hochschule Hannover Proteína do fator 1 para utilização no tratamento ou prevenção de doenças
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8921598A (en) * 1997-08-29 1999-03-16 Human Genome Sciences, Inc. 29 human secreted proteins
EP1056847A2 (en) * 1998-02-27 2000-12-06 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
ES2312205T3 (es) * 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
EP1068307A1 (en) * 1998-03-31 2001-01-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
MXPA01002546A (es) * 1998-09-14 2004-06-11 Genentech Inc Promocion o inibhicion de angiogenesis y cardiovascularizacion.
KR100529270B1 (ko) * 1998-12-01 2005-11-21 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
AU2399300A (en) * 1999-03-08 2000-09-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1263948A2 (en) * 1999-03-08 2002-12-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR100543857B1 (ko) * 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
EP2075253A1 (en) * 2000-06-23 2009-07-01 Genentech, Inc. Compositions and methds for the diagnosis and treatment of disorders involving angiogensis

Similar Documents

Publication Publication Date Title
EP0617126B1 (en) Polypeptide capable of inhibiting the binding between human IL-6 and its receptor
JP2025143268A (ja) 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
EP3760642A1 (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
CN111018987B (zh) 一种能与人内皮素受体特异性结合的抗体及其应用
RU2183215C2 (ru) Конъюгат для стимулирования иммунной реакции против клетки-мишени, способ лечения злокачественных опухолей у млекопитающего
US6627439B2 (en) Antibodies against SEMP1(p23)
HK1218554A1 (zh) 人pac1抗體
JPS626000A (ja) ハイブリドインタ−フエロン及びその製造方法
JP4308322B2 (ja) インターフェロンアルファ／ベータ受容体に対する抗体
CN116917326A (zh) 抗her-2/trop-2构建体及其用途
JP2020509737A5 (enExample)
JP2008508858A (ja) マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害
TW416960B (en) Reshaped human antibody to human interleukin-8
WO2021008519A1 (zh) ETA抗体与TGF-βTrap的融合蛋白质，以及其药物组合物和应用
KR102669444B1 (ko) Etar 항체 및 이의 약학 조성물 및 용도
JP2003530871A (ja) インテグリン／接着因子アンタゴニスト
EP1283217B1 (en) Antibodies against the IL-8 receptor, and their therapeutic uses
WO2006046661A1 (ja) インターロイキン－６阻害剤
KR100277769B1 (ko) 항-파스 재조합 항체 및 이에 대한 디엔에이
CA3180251A1 (en) Cytokine conjugates
WO2023222035A1 (zh) 抗tigit抗体与il2的融合蛋白或其变体及其应用
US20230391863A1 (en) Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
US20240343788A1 (en) Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof
US20240400658A1 (en) Anti-periostin humanized monoclonal antibody, and preparation method therefor and use thereof
KR20250117442A (ko) TNF-α 및 IL-17A를 표적하는 이중특이적 융합 단백질 및 이의 용도